Protein-protein interactions: Mechanisms and modification by drugs

Journal of Molecular Recognition

Volumn 15, Issue 6, 2002, Pages 405-422

  Veselovsky, A V ^a   Ivanov, Yu D ^a   Ivanov, A S ^a   Archakov, A I ^a   Lewi, P ^b   Janssen, P ^b  

^a INSTITUTE OF BIOMEDICAL CHEMISTRY   (Russian Federation)

^b Center for Molecular Design   (Belgium)

Author keywords

Antagonist; Dimerization; Drug design; Inhibitors; Protein complex; Protein surface; Protein protein interaction; Thermodynamics

Indexed keywords

ANIMALS; BINDING SITES; HUMANS; PROTEIN BINDING; PROTEIN INTERACTION MAPPING; PROTEINS;

EID: 0036872411     PISSN: 09523499     EISSN: None     Source Type: Journal    
DOI: 10.1002/jmr.597     Document Type: Review

References (289)

1. Abdalla S, Zaki E, Lother H, Quitterer U. 1999. Involvement of the amino terminus of the B-2 receptor in agonist-induced receptor dimerization. J. Biol. Chem. 274: 26079-26084.
2. Ahmad KF, Engel CK, Prive GG. 1998. Crystal structure of the BTB domain from PLZF. Proc. Natl Acad. Sci. USA 95: 12123-12128.
3. Alattia JR, Kurokawa H, Ikura M. 1999. Structural view of adherin-mediated cell-cell adhesion. Cell Mol. Life Sci. 55: 359-367.
4. Alligood KJ, Charifson PS, Crosby R, Consler TG, Feldman PL, Gampe RT Jr., Gilmer TM, Jordan SR, Milstead MW, Mohr C, Peel MR, Rocque W, Rodriguez M, Rusnak DW, Shewchuk LM, Sternbach DD. 1998. The formation of a covalent complex between a dipeptide ligand and the src SH2 domain. Bioorg. Med. Chem. Lett. 8: 1189-1194.
5. Amara JF, Clackson T, Rivera VM, Guo T, Keenan T, Natesan S, Pollock R, Yang W, Courage NL, Holt DA, Gilman M. 1997. A versatile synthetic dimerizer for the regulation of protein-protein interactions. Proc. Natl Acad. Sci. USA 94: 10618-10623.
6. Andrade-Gordon P, Maryanoff BE, Derian CK, Zhang HC, Addo MF, Darrow AL, Eckardt AJ, Hoekstra WJ, McComsey DF, Oksenberg D, Reynolds EE, Santulli RJ, Scarborough RM, Smith CE, White KB. 1999. Design, synthesis, and biological characterization of a peptide-mimetic antagonist for a tethered-ligand receptor. Proc. Natl Acad. Sci. USA 96: 12257-12262.
7. Aoki M, Ishimori K, Fukada H, Takahashi K, Morishima I. 1998a. Isothermal titration calorimetric studies on the asociations of putidaredoxin to NADH-puridaredoxin reductase and P450cam. Biochim. Biophys. Acta 1384: 180-188.
8. Aoki M, Ishimori K, Morishima I. 1998b. Roles of negatively charged surface residues of putidaredoxin in interactions with redox partners in P450cam monooxygenase system. Biochim. Biophys. Acta 1386: 157-167.
9. Appling DR. 1999. Genetic approaches to the study of protein-protein interactions. Methods 19: 338-349.
10. Archakov AI, Ivanov YuD. 1999. The optical biosensor study of the protein-protein interactions with cytochrome P450s. In Biophysics of Electron Transfer and Molecular Bioelectronics. Plenum: New York; 173-194.
11. Ast O, Jentsch KD, Schramm HJ, Hunsmann G, Luke W, Petry H. 1998. A rapid and sensitive bacterial assay to determine the inhibitory effect of 'interface' peptides on HIV-1 protease coexpressed in Escherichia coli. J. Virol. Meth. 71: 77-85.
12. Austin DJ, Crabtree GR, Schreiber SL. 1994. Proximity versus allostery: the role of regulated protein dimerization in biology. Chem. Biol. 1: 131-136.
13. Aviezer D, Cotton S, David M, Segev A, Khaselev N, Galili N, Gross Z, Yayon A. 2000. Porphyrin analogues as novel antagonists of fibroblast growth factor and vascular endothelial growth factor receptor binding that inhibit endothelial cell proliferation, tumor progression, and metastasis. Cancer Res. 60: 2973-2980.
14. Banci L, Benedetto M, Bertini I, Delconte R, Piccioli M, Viezzoli MS. 1998. Solution structure of reduced monomeric Q133M2 copper, zinc superoxide dismutase (SOD). Why is SOD a dimeric enzyme? Biochemistry 37: 11780-11791.
15. Bass J, Chiu G, Argon Y, Steiner DF. 1998. Folding of insulin receptor monomers is facilitated by the molecular chaperones calnexin and calreticulin and impaired by rapid dimerization. J. Cell Biol. 141: 637-646.
16. Beaulieu PL, Cameron DR, Ferland JM, Gauthier J, Ghiro E, Gillard J, Gorys V, Poirier M, Rancourt J, Wernic D, Llinas-Brunet M, Betageri R, Cardozo M, Hickey ER, Ingraham R, Jakes S, Kabcenell A, Kirrane T, Lukas S, Patel U, Proudfoot J, Sharma R, Tong L, Moss N. 1999. Ligands for the tyrosine kinase p561ck SH2 domain: discovery of potent dipeptide derivatives monocharged, nonhydrolyzable phosphate replacements. J. Med. Chem. 42: 1757-1766.
17. Beebe KD, Wang P, Arabaci G, Pei DH. 2000. Determination of the binding specificity of the SH2 domains of protein tyrosine phosphatase SHP-1 through the screening of a combinatorial phosphotyrosyl peptide library. Biochemistry 39: 13251-13260.
18. Beeckmans S. 1999. Chromatographic methods to study protein-protein interactions. Methods 19: 278-305.
19. Beeley NRA. 2000. Can peptides be mimicked? Drug Discov. Today 5: 354-363.
20. Behlke J, Heidrich K, Naumann M, Muller EC, Otto A, Reuter R, Kriegel T. 1998. Hexokinase 2 from Saccharomyces cerevisiae: regulation of oligomeric structure by in vivo phosphorylation at serine-14. Biochemistry 37: 11989-11995.
21. Bell SL, Khatri IA, Xu GQ, Forstner JF. 1998. Evidence that a peptide corresponding to the rat Muc2 C-terminus undergoes disulphide-mediated dimerization. Eur. J. Biochem. 253: 123-131.
22. Belshaw PJ, Ho SN, Crabtree GR, Schreiber SL. 1996. Controlling protein association and subcellular localization with a synthetic ligand that induces heterodimerization of proteins. Proc. Natl Acad. Sci. USA 93: 4604-4607.
23. Betts MJ, Sternberg MJE. 1999. An analysis of conformational changes on protein-protein association: implications for predictive docking. Protein Engng. 12: 271-283.
24. Bhattacharya A, Bhattacharyya B, Roy S. 1996. Fluorescence energy transfer measurement of distances between ligand binding sites of tubulin and its implication for protein-protein interaction. Protein Sci. 5: 2029-2036.
25. Blatch GL, Lassle M. 1999. The tetratricopeptide repeat: a structural motif mediating protein-protein interactions. Bioessays 21: 932-939.
26. Blau AC, Petrson KR, Drachman JG, Spencer DM. 1997. A proliferation swich for genetically modified cells. Proc. Natl Acad. Sci. USA 94: 3076-3081.
27. Bochkareva E, Safro M, Girshovich A. 1999. Interaction of 4, 4′-dithiodipyridine with Cys(458) triggers disassembly of GroEL. J. Biol. Chem. 274: 20756-20758.
28. Bogan AA, Thorn KS. 1998. Anatomy of hot spots in protein interfaces. J. Mol. Biol. 280: 1-9.
29. Bouras A, Boggetto N, Benatalah Z, Derosny E, Sicsic S, Reboudravaux M. 1999. Design, synthesis, and evaluation of conformationally constrained tongs, new inhibitors of HIV-1 protease dimerization. J. Med. Chem. 42: 957-962.
30. Bradshaw JM, Mitaxov V, Waksman G. 2000. Mutational investigation of the specificity determining region of the Src SH2 domain. J. Mol. Biol. 299: 521-535.
31. Brady GP, Sharp KA. 1997. Entropy in protein folding and in protein-protein interactions. Curr. Opin. Struct. Biol. 7: 215-221.
32. 2+ GroEL interactions. J. Biol. Chem. 273: 3257-3263.
33. Brickner M, Chmielewski J. 1998. Inhibiting the dimeric restriction endonuclease EcoRI using interfacial helical peptides. Chem. Biol. 5: 339-343.
34. Burke TR Jr, Luo J, Yao Z-J, Gao Y, Zhao H. 1999. Monocarboxylic-based phosphotyrosyl mimetics in the design of Grb2 SH2 domain inhibitors. Bioorg. Med. Chem. Lett. 9: 347-352.
35. Burke TR, Yao ZJ, Gao Y, Wu JX, Zhu XF, Luo JH, Guo RB, Yang DJ. 2001. N-terminal carboxyl and tetrazole-containing amides as adjuvants to Grb2 SH2 domain ligand binding. Bioorg. Med. Chem. 9: 1439-1445.
36. Camacho CJ, Weng ZP, Vajda S, Delisi C. 1999. Free energy landscapes of encounter complexes in protein-protein association. Biophys. J. 76: 1166-1178.
37. Camacho CJ, Kimura SR, Delisi C, Vajda S. 2000. Kinetics of desolvatation-mediated protein-protein binding. Biophys. J. 78: 1094-1105.
38. Carr PA, Erickson HP, Palmer AG. 1997. Backbone dynamics of homologous fibronectin type III cell adhesion domain from fibronectin and tenascin. Structure 5: 949-959.
39. Chackalamannil S, Doller D, Eagen K, Czarniecki M, Ahn HS, Foster CJ, Boykow G. 2001. Potent, low molecular weight thrombin receptor antagonists. Bioorg. Med. Chem. Lett. 11: 2851-2853.
40. Chen C, Zhu YF, Liu XJ, Lu ZX, Xie Q, Ling N. 2001. Discovery of a series of nonpeptide small molecules that inhibit the binding of insulin-like growth factor (IGF) to IGF-binding proteins. J. Med. Chem. 44: 4001-4010.
41. Chen H, Shi M, Guo ZY, Tang YH, Qiao ZS, Liang ZH, Feng YM. 2000. Four new monomeric insulins obtained by alanine scanning the dimer-forming surface of the insulin molecule. Protein Engng. 13: 779-782.
42. Chirlando R, Keown MB, Mackay GA, Lewis MS, Unkeles JC, Gould HJ. 1995. Stochiometry and thermodinamics of the interaction between the Fc fragment of human IgG1 and its low-affinity receptor Fc gamma RIII. Biochemistry 34: 13320-13327.
43. Chrunyk BA, Rosner MH, Cong Y, McColl AS, Otterness IG, Daumy GO. 2000. Inhibiting protein-protein interactions: a model for antagonist design. Biochemistry 39: 7092-7099.
44. Clackson T, Wells JA. 1995. A hot spot of binding energy in a hormone-receptor interface. Science 267: 383-386.
45. Clackson T, Yang W, Rozamus LW, Hatada M, Amara JF, Rollins CT, Stevenson LF, Magari SR, Wood SA, Courage NL, Lu XD, Cerasoli F, Gilman M, Holt DA. 1998. Redesigning an FKBP-ligand interface to generate chemical dimirizers with novel specificity. Proc. Natl Acad. Sci. USA 95: 10437-10442.
46. Clemons PA. 1999. Design and discovery of protein dimerizers. Curr. Opin. Chem. Biol. 3: 112-115.
47. Cochran AG. 2000. Antagonists of protein-protein interactions. Chem. Biol. 7: R85-R94.
48. Cochran AG. 2001. Protein-protein interfaces: mimics and inhibitors. Curr. Opin. Chem. Biol. 5: 654-659.
49. Cody WL, Lin ZW, Panek RL, Rose DW, Rubin JR. 2000. Progress in the development of inhibitors of SH2 domains. Curr. Pharm. Des. 6: 59-98.
50. Cohen FE, Prusiner SB. 1998. Pathologic conformations of prion proteins. A. Rev. Biochem. 67: 793-819.
51. Crump CM, Williams JL, Stephens DJ, Banting G. 1998. Inhibition of the interaction between tyrosine-based motifs and the medium chain subunit of the AP-2 adaptor complex by specific tyrphostins. J. Biol. Chem. 273: 28073-28077.
52. Cunha CA, Romao MJ, Sadeghi SJ, Valetti F, Gilardi G, Soares CM. 1999. Effects of protein-protein interactions on electron transfer: docking and electron transfer calculations for complexes between flavodoxin and c-type cytochromes. J. Biol. Inorg. Chem. 4: 360-374.
53. Cunningham BC, Wells JA. 1997. Minimized proteins. Curr. Opin. Struct. Biol. 7: 457-462.
54. Dalgarno DC, Botfield MC, Rickles RJ. 1997. SH3 domains and drug design: ligands, structure, and biological function. Biopolymers 43: 383-400.
55. Dall'Acqua W, Goldman ER, Lin W, Teng C, Tsuchiya D, Li H, Ysern X, Braden BC, Li Y, Smith-Gill SJ, Mariuzza RA. 1998. A mutational analysis of binding interactions in an antigen-antibody protein-protein complex. Biochemistry 37: 7981-7991.
56. Dare S, Schumacher J, Rousseau P, Fourment J, Ebel C, Kahn D. 1999. Phosphorylation-induced dimerization of the FixJ receiver domain. Mol. Microbiol. 34: 504-511.
57. Davidson JP, Martin SF. 2000. Use 1, 2, 3-trisubstituted cyclopropanes as conformationally constrained peptide mimics in SH2 antagonists. Tetrahedron Lett. 41: 9459-9464.
58. Davies DR, Cohen GH. 1996. Interactions of protein antigen with antibodies. Proc. Natl Acad. Sci. USA 93: 7-12.
59. Davis DA, Newcomb FM, Moskovitz J, Wingfield PT, Stahl SJ, Kaufman J, Fales HM, Levine RL, Yarchoan R. 2000. HIV-2 protease is inactivated after oxidation at the dimer interface and activity can be partly restored with methionine sulphoxide reductase. Biochem. J. 346: 305-311.
60. Davis SJ, Davies EA, Tucknott MG, Jones EY, van der Merwe PA. 1998. The role of charged residues mediating low affinity protein-protein recognition at the cell surface by CD2. Proc. Natl Acad. Sci. USA 95: 5490-5494.
61. Davydov DR, Knyushko TV, Kanaeva IP, Koen YM, Samenkova NF, Archkov AI, Hui Bon Hoa G. 1996. Interactions of cytochrome P450 2B4 with NADPH-cytochrome P450 reductase studied by fluorescent probe. Biochimie 78: 734-743.
62. Dear TN, Hainzl T, Follo M, Nehls M, Wilmore H, Matena K, Boehm T. 1997. Identification of interaction partners for the basic-helix-loop-helix protein E47. Oncogene 14: 891-898.
63. Decrescenzo G, Grothe S, Lortie R, Debanne MT, Oconnormccourt M. 2000. Real-time kinetic studies on the interaction of transforming growth factor alpha with the epidermal growth factor receptor extracellular domain reveal a conformational change model. Biochemistry 39: 9466-9476.
64. Digard P, Williams KP, Hensley P, Brooks IS, Dahl CE, Coen DM. 1995. Specific inhibition of herpes simplex virus DNA polymerase by helical peptides corresponding to the subunit interface. Proc. Natl Acad. Sci. USA 92: 1456-1460.
65. Dobrosotskaya I, Guy RK, James GL. 1997. MAGI-1, a membrane-associated guanylate kinase with a unique arrangement of protein-protein interaction domains. J. Biol. Chem. 272: 31589-31597.
66. Dong LQ, Porter S, Hu DR, Liu F. 1998. Inhibition of hGrb10 binding to insulin receptor by functional domain-mediated oligomerization. J. Biol. Chem. 273: 17720-17725.
67. Drozdov-Tikhomirov LN, Linde DM, Poroikov VV, Alexandrov AA, Skurida GI. 2001. Molecular mechanisms of protein-protein recognition: whether the surface placed charged residues determine the recognition process? J. Biomol. Struct. Dyn. 19: 279-284.
68. Dunphy J, Linder ME. 1998. Signalling functions of protein palmitoylation. Biochim. Biophys. Acta 1436: 245-261.
69. Eaton SR, Cody WL, Doherty AM, Holland DR, Panek RL, Lu GH, Dahring TK, Rosa DR. 1998. Design of peptidomimetics that inhibit the association of phosphatidylinisitol 3-kinase with platelet-derived growth factor-beta receptor and possess cellular activity. J. Med. Chem. 41: 4329-4342.
70. Ehring H. 1999. Hydrogen exchange/electrospray ionization mass spectrometry studies of structural features of proteins and protein/protein interactions. Anal. Biochem. 267: 252-259.
71. Eisenhaber F, Argos P. 1996. Hydrophobic regions on protein surfaces: definition based on hydration shell structure and a quick method for their computation. Protein Engng. 9: 1121-1133.
72. Eisenmessers EZ, Post CB. 1998. Insights into phosphorilation control of protein-protein association from the NMR structure of a band 3 peptide inhibitor bound to glyceraldehyde-3-phosphate dehydrogenase. Biochemistry 37: 867-877.
73. Eubanks S, Nguyen TL, Peyton D, Breslow E. 2000. Modulation of dimerization, binding, stability, and folding by mutation of the neurophysin subunit interface. Biochemistry 39: 8085-8094.
74. Eyster KM. 1998. Introduction to Signal Transduction. A primer for untangling the web of intracellular messengers. Biochem. Pharmac. 55: 1927-1938.
75. Fancy DA, Kodadek T. 1999. Chemistry for the analysis of protein-protein interactions: rapid and efficient cross-linking triggered by long wavelength light. Proc. Natl Acad. Sci. USA 96: 6020-6024.
76. Findeis MA. 2000. Approaches to discovery and characterization of inhibitors of amyloid beta-peptide polymerization. Biochim. Biophys. Acta 1502: 76-84.
77. Foti M, Cartier L, Piguet V, Lew DP, Carpentier JL, Trono D. Krause KH. 1999. The HIV protein alters Ca2+ signaling in myelomonocytic cells through SH3-mediated protein-protein interactions. J. Biol. Chem. 274: 24765-34772.
78. Freidinger RM. 1999. Nonpeptide ligands for peptide and protein receptors. Curr. Opin. Chem. Biol. 3: 395-406.
79. Fretz H, Furet P, Garciaecheverria C, Rahuel J, Schoepfer J. 2000. Structure-based design of compounds inhibiting Grb2-SH2 mediated protein-protein interactions in signal transduction pathways. Curr. Pharm. Des. 6: 1777-1796.
80. Fuh G, Pisabarro MT, Li Y, Quan C, Lasky LA, Sidhu SS. 2000. Analysis of PDZ domain-ligand interactions using carboxyl-terminal phage display. J. Biol. Chem. 275: 21486-21491.
81. Fujita T, Nakajima M, Inoue Y, Nose T, Shimohigashi Y. 1999. A novel molecular design of thrombin receptor antagonist. Bioorg. Med. Chem. Lett. 9: 1351-1356.
82. Furet P, Garcia-Echeverria C, Gay B, Schoepfer J, Zeller M, Rahuel J. 1999. Structure-based design, synthesis, and X-ray crystallography of a high-affinity antagonist of the -SH2 domain containing an asparagine mimetic. J. Med. Chem. 42: 2358-2363.
83. Furet P, Caravatti G, Denholm AA, Faessler A, Fretz H, Garcia-Echeverria C, Gay B, Irving E, Press NJ, Rahuel J, Schoepfer J, Walker CV. 2000. Structure-based design and synthesis of phosphinate isosteres of phosphotyrosine for incorporation in Grb2-SH2 domain inhibitors. Part 1. Bioorg. Med. Chem. Lett. 10: 2337-2341.
84. Gabdoulline and Wade. 1999. J. Mol. Recognit. 12: 226-234.
85. Gao Y, Wu L, Luo JH, Guo R, Yang D, Zhang ZY, Burke TR Jr. 2000. Examination of novel non-phosphorus-containing phosphotyrosyl mimetics against protein-tyrosine phosphatase-1B and demonstration of differential affinities toward Grb2 SH2 domains. Bioorg. Med. Chem. Lett. 10: 923-927.
86. Garciaecheverria C. 2001. Antagonists of the Src homology 2 (SH2) domains of Grb2, Src, Lck and ZAP-70. Curr. Med. Chem. 8: 1589-1604.
87. Garnier C, Barbier P, Gilli R, Lopez C, Peyrot V, Briand C. 1998. Head-shock protein 90 (hsp90) binds to tubulin dimer and inhibits microtubule formation. Biochem. Biophys. Res. Commun. 250: 414-419.
88. Gay B, Suarez S, Caravatti G, Furet P, Meyer T, Schoepfer J. 1999a. Selective GRB2 SH2 inhibitors as anti-Ras therapy. Int. J. Cancer 83: 235-241.
89. Gay B, Suarez S, Weber C, Rahuel J, Fabbro D, Furet P, Schoepfer J. 1999b. Effect of potent and selective inhibitors of Gbr2 SH2 domain on cell motility. J. Biol. Chem. 274: 23311-23315.
90. Ghosh I, Chmielewski J. 1998. A β-sheet peptide inhibitors of E47 dimerization and DNA binding. Chem. Biol. 5: 439-445.
91. Ghosh I, Issac R, Chmielewski J. 1999. Structure-function relationship in a beta-sheet peptide inhibitor of E47 dimerization and DNA binding. Bioorg. Med. Chem. 7: 61-66.
92. Gibas CJ, Subramaniam S, McCammon JA, Braden BC, Poljak RJ. 1997. pH dependence of antibody/lysozyme complexation. Biochemistry 36: 15599-15614.
93. Glaser RW, Hausdorf G. 1996. Binding kinetics of an antibody against HIV p24 core protein measured with real-time biomolecular interaction analysis suggest a slow conformation change in antigen p24. J. Immunol. Meth. 189: 1-14.
94. Gloss LM, Matthews CR. 1998. The barriers in the bimolecular and unimolecular folding reactions of the dimeric core domain of Escherichia coli Trp repressor are dominated by enthalpic contributions. Biochemistry 37: 16000-16010.
95. Gomez J, Freire E. 1995. Thermodynamic mapping of the inhibitor site of the aspartic protease endothiapepsin. J. Mol. Biol. 252: 337-350.
96. Gomez-Moreno C, Martinez-Julvez M, Medina M, Hurley JK, Tollin G. 1998. Protein-protein interaction in electron transfer reactions: the ferredoxin/flavodoxin/ferredoxin: NADP + reductase system from Anabaena. Biochimie 80: 837-846.
97. Gong XS, Wen JQ, Fisher NE, Young S, Howe CJ, Bendall DS, Gray JC. 2000. The role of individual lysine residues in the basic patch on turnip cytochrome f for electrostatic interactions with plastocyanin in vitro. Eur. J. Biochem. 267: 3461-3468.
98. Gotz C, Scholtes P, Prowald A, Schuster N, Nastainczyk W, Montenarh M. 1999. Protein kinase CK2 interacts with a multiprotein binding domain of p53. Mol. Cell Biochem. 191: 111-120.
99. Grant GA, Xu XL, Hu ZQ. 2000. Removal of the tryptophan 139 side chain in Escherichia coli D-3-phosphoglycerate dehydrogenase produces a dimeric enzyme without cooperative effects. Arch. Biochem. Biophys. 375: 171-174.
100. Grucza RA, Bradshaw JM, Mitaxov V, Waksman G. 2000. Role of electrostatic interactions in SH2 domain recognition: salt-dependence of tyrosyl-phosphorylated peptide binding to the tandem SH2 domain of the Syk kinase and the single SH2 domain of the Src kinase. Biochemistry 39: 10072-10081.
101. Hart CP, Martin JE, Reed MA, Keval AA, Pustelnik MJ, Northrop JP, Grove JR. 1999. Potent inhibitory ligands of the GRB2 SH2 domain from recombinant peptide libraries. Cell Signal. 11: 453-464.
102. Herrmann H, Aebi U. 1998. Intermediate filament assembly: fibrillogenesis is driven by decisive dimer-dimer interactions. Curr. Opin. Struct. Biol. 8: 177-185.
103. Hilpert K, Behlke J, Scholz C, Misselwitz R, Schneider-Mergener J, Hohne W. 1999. Interaction of the caspid protein p24 (HIV-1) with sequence-derived peptides. Influence on p24 dimerization. Virology 254: 6-10.
104. Ho SN, Biggar SR, Spencer DM, Schreiber SL, Crabtree GR. 1996. Dimeric ligands define a role for transcriptional activation domains in reinitiation. Nature 382: 822-826.
105. Hoekstra WJ, Hulshizer BL, McComsey DF, Andrade-Gordon P, Kauffman JA, Addo MF, Oksenberg D, Scarborough RM, Maryanoff BE. 1998. Thrombin receptor (PAR-1) antagonists. Heterocycle-based peptidomimetics of the SFLLR agonist motif. Bioorg. Med. Chem. Lett. 8: 1649-1654.
106. Holwerda B. 1999. Activity in monomers of human cytomegalovirus protease. Biochem. Biophys. Res. Commun. 259: 370-373.
107. Hu JC, Kornacker MG, Hochschild A. 2000a. Escherichia coli one-and two-hybrid systems for the analysis and identification of protein-protein interactions. Methods 20: 80-94.
108. Hu ZJ, Ma BY, Wolfson H, Nussinov R. 2000b. Conservation of polar residues as hot spots at protein interfaces. Proteins 39: 331-342.
109. Huang HW, Chen WC, Wu CY, Yu HC, Lin WY, Chen ST, Wang KT. 1997. Kinetic studies of the inhibitory effects of propeptides subtilisin BPN' and Carlsberg to bacterial serine proteases. Protein Engng 10: 1227-1233.
110. Hubbard SJ, Argos P. 1994. Cavities and packing at protein interfaces. Protein Sci. 3: 2194-2206.
111. Imai Y, Moralez A, Andag U, Clarke JB, Busby WH, Clemmons DR. 2000. Substitutions for hydrophobic amino acids in the N-terminal domains of IGFBP-3 and-5 markedly reduce IGF-I binding and alter their biologic actions. J. Biol. Chem. 275: 18188-18194.
112. Ivanov YD, Kanaeva IP, Kuznetsov VY, Lehnerer M, Schulze J, Hlavica P, Archakov AI. 1999a. The optical biosensor studies on the role of hydrophobic tails of NADPH-cytochrome P450 reductase and cytochromes P450 2B4 and b5 upon productive complex formation within a monomeric reconstituted system. Arch. Biochem. Biophys. 362: 87-93.
113. Ivanov YD, Usanov SA, Archakov AI. 1999b. The optical biosensor studies on the productive complex formation between the components of cytochrome P450scc dependent monooxygenase system. Biochem. Mol. Biol. Int. 47: 327-336.
114. Ivanov Yu, Kanaeva I, Archakov A. 2000. Optical biosensor studys of ternary complex formation in a cytochrome P450 2B4 system. Biochem. Biophys. Res. Commun. 273: 750-752.
115. Ivanov YD, Kanaeva IP, Karuzina IP, Archakov AI, Hui Bon Hoa G, Sligar SG. 2001. Molecular recognition in the P450cam monooxygenase system: direct monitoring of protein-protein interaction by using optical biosensor. Arch. Biochem. Biophys. 391: 255-264.
116. Jackson RM. 1999. Comparison of protein-protein interactions in serine protease-inhibitor and antibody-antigen complexes: Implications for the protein docking problem. Protein Sci. 8: 603-613.
117. Janin J. 1995. Principles of protein-protein recognition from structure to thermodynamics. Biochimie 77: 497-505.
118. Janin J. 1999. Wet and dry interfaces: the role of solvent in protein-protein and protein-DNA recognition. Struct. Fold. Des. 7: 277-279.
119. Janin J. 2000. Kinetics and thermodynamics of protein-protein interactions. In Protein-Protein Recognition. Oxford University Press: New York; 1-32.
120. Jones S, Thornton JM. 1996. Principles of protein-protein interactions. Proc. Natl Acad. Sci. USA 93: 13-20.
121. Jones S, Thornton JM. 2000. Analysis and classification of protein-protein interactions from a structural perspective. In Protein-Protein Recognition. Oxford University Press: New York; 33-59.
122. Ju H, Venema VJ, Marrero MB, Venema RC. 1998. Inhibitory interactions of the brakinin B2 receptor with endothelial nitric-oxide synthase. J. Biol. Chem. 273: 24025-24029.
123. Kameshita I, Ishida A, Fujisawa H. 1998. Analysis of protein-protein interaction by two-dimensional affinity electrophoresis. Anal. Biochem. 262: 90-92.
124. Kato M, Iwashita T, Takeda K, Akhand AA, Liu W, Yoshihara M, Hossain K, Wu J, Du J, Oh C, Kawamoto Y, Suzuki H, Takahashi M, Nakashima I. 2000. Ultraviolet light induces redox reaction-mediated dimerization and superactivation of oncogenic Ret tyrosine kinases. Mol. Biol. Cell 11: 93-101.
125. Keenan T, Yaeger DR, Courage NL, Rollins CT, Pavone ME, Rivera VM, Yang W, Guo T, Amara JF, Clackson T, Gilman M, Holt DA. 1998. Synthesis and activity of bivalent FKBP12 ligands for the regulated dimerization of proteins. Bioorg. Med. Chem. 6: 1309-1335.
126. Kehoe JW, Bertozzi CR. 2000. Tyrosine sulfation: a modulator of extracellular protein-protein interactions. Chem. Biol. 7: R57-R61.
127. Kim HK, Nam JY, Han MY, Lee EK, Choi JD, Bok SH, Kwon BM. 1999. Actinomycin D as a novel SH2 domain ligand inhibits Shc/Grb2 interaction in B104-1-1 (neu*-transformed NIH3T3) and SAA (hEGFR-overexpressed NIH3T3) cells. FEBS Lett. 453: 174-178.
128. Kimura SR, Brower RC, Vajda S, Camacho CJ. 2001. Dynamical view of the positions of key side chains in protein-protein recognition. Biophys. J. 80: 635-642.
129. Kiselyova OI, Yaminsky IV, Ivanov YuD, Kanaeva IP, Kuznetsov VYu, Archakov AI. 1999. AFM study of membrane proteins, cytochrome P450 2B4 and NADPH-cytochrome P450 reductase, and of their complex formation. Arch. Biochem. Biophys. 371: 1-7.
130. Klemm JD, Schreiber SL, Crabtree GR. 1998. Dimerization as a regulatory mechanism in signal transduction. A. Rev. Immunol. 16: 569-592.
131. Kojima S, Minagawa T, Miura K. 1998. Tetriary structure formation in the propeptide of subtilisin BPN' by successive amino acid replacements. J. Mol. Biol. 277: 1007-1013.
132. Koltzscher M, Gerke V. 2000. Identification of hydrophobic amino acid residues involved in the formation of S100P homodimers in vivo. Biochemistry 39: 9533-9539.
133. Kopytek SJ, Standaert RF, Dyer JCD, Hu JC. 2000. Chemically induced dimerization of dihydrofolate reductase by a homobifunctional dimer of methotrexate. Chem. Biol. 7: 313-321.
134. Kozlov G, Gehring K, Ekiel I. 2000. Solution structure of the PDZ2 domain from human phosphatase hPTP1E and its interaction with C-terminal peptides from the Fas receptors. Biochemistry 39: 2572-2580.
135. Kuhlmann UC, Pommer AJ, Moore GR, James R, Kleanthous C. 2000. Specificity in protein-protein interactions: The structural basis for dual recognition in endonuclease colicin-immunity protein complexes. J. Mol. Biol. 301: 1163-1178.
136. Laitinen OH, Marttila AT, Airenne KJ, Kulik T, Livnah O, Bayer EA, Wilchek M, Kulomaa MS. 2001. Biotin induces tetramerization of a recombinant monomeric avidin - A model for protein-protein interactions. J. Biol. Chem. 276: 8219-8224.
137. Larsen TA, Olson AJ, Goodsell DS. 1998. Morphology of protein-protein interfaces. Structure 6: 421-427.
138. Le F, Stomski F, Woodcock JM, Lopez AF, Gonda TJ. 2000. The role of disulfide-linked dimerization in interleukin-3 receptor signaling and biological activity. J. Biol. Chem. 275: 5124-5130.
139. Leavitt S, Freire E. 2001. Direct measurement of protein binding energetics by isothermal titration calorimetry. Curr. Opin. Struct. Biol. 11: 560-566.
140. Lebl M. 1999. New technique for high-throughput synthesis. Bioorg. Med. Chem. Lett. 9: 1305-1310.
141. Lehnerer M, Schulze J, Pernecky SJ, Lewis DFV, Eulitz M, Hlavica P. 1998. Influence of mutation of the amino-terminal signal anchor sequence of cytochrome P450 2B4 on the enzyme structure and electron transfer processes. J. Biochem. 124: 396-403.
142. Li S, Satoh T, Korngold R, Huang Z. 1998. CD4 dimerization and oligomerization: implications for T-cell function and structure-based drug design. Immunol. Today 19: 455-62.
143. Li YL, Li HM, Smithgill SJ, Mariuzza RA. 2000. Three-dimensional structures of the free and antigen-bound Fab from monoclonal antilysozyme antibody HyHEL-63. Biochemistry 39: 6296-6309.
144. Lijnzaad P, Argos P. 1997. Hydrophobic patches on protein subunit interfaces: Characteristics and prediction. Proteins 28: 333-343.
145. Lin CT, Kuo TJ, Shaw JF, Kao MC. 1999. Characterization of the dimer-monomer equilibrium of the papaya copper/zinc superoxide dismutase and its equilibrium shift by a single amino acid mutation. J. Agric. Food Chem. 47: 2944-2949.
146. Liu JO. 1999. Recruitment of proteins to modulate protein-protein interactions. Chem. Biol. 6: R213-R216.
147. Liuzzi M, Deziel R, Moss N, Beaulieu P, Bonneau AM, Bousquet C, Chafouleas JG, Garneau M, Jaramillo J, Krogsrud RL et al. 1994. A potent peptidomimetic inhibitor of HSV ribonucleotide reductase with antiviral activity in vivo. Nature 372: 695-698.
148. Lo Conte L, Chothia C, Janin J. 1999. The atomic structure of protein-protein recognition sites. J. Mol. Biol. 285: 2177-2198.
149. Lomax ME, Barnes DM, Hupp TR, Picksley SM, Camplejohn RS. 1998. Characterization of p53 oligomerization domain mutations isolated from Li-Fraumeni and Li-Fraumeni like family members. Oncogene 17: 643-649.
150. Lou YC, Lung FD, Pai MT, Tzeng SR, Wei SY, Roller PP, Cheng JW. 1999. Solution structure and dynamics of G1TE, a nonphosphorylated cyclic peptide inhibitor for the Grb2 SH2 domain. Arch. Biochem. Biophys. 372: 309-314.
151. Loughney DA, Murray WV, Jolliffe LK. 1999. Application of virtual screening tools to a protein-protein interaction: Database mining studies on the growth hormone receptor. Med. Chem. Res. 9: 579-591.
152. MacCorkle RA, Freeman KW, Spencer DM. 1998. Synthetic activation of caspases: artificial death switches. Proc. Natl Acad. Sci. USA 95: 3655-3660.
153. Markus M, Benezra R. 1999. Two isoforms of protein disulfide isomerase alter the dimerization status of E2A proteins by a redox mechanism. J. Biol. Chem. 274: 1040-1049.
154. Maroun RG, Gayet S, Benleulmi MS, Porumb H, Zargarian L, Merad H, Leh H, Mouscadet JF, Troalen FR, Fermandjian S. 2001. Peptide inhibitors of HIV-1 integrase dissociate the enzyme oligomers. Biochemistry 40: 13840-13848.
155. Marrone TJ, Briggs JM, McCammon JA. 1997. Structure-based drug design: computational advances. A. Rev. Pharmac. Toxicol. 37: 71-90.
156. Martin C, Hartley R, Mauguen Y. 1999a. X-ray structural analysis of compensating mutations at the barnase-barstar interface. FEBS Lett. 452: 128-132.
157. Martin DC, Pastralandis SC, Kantrowitz ER. 1999b. Amino acid substitutions at the subunit interface of dimeric Escherichia coli alkaline phosphatase cause reduced structural stability. Protein Sci. 8: 1152-1159.
158. Marusawa H, Setoi H, Kuroda A, Sawada A, Seki J, Motoyama Y, Tanaka H. 1999. Synthesis and biological activity of 4-methyl-3, 5-dioxane derivatives as thromboxane A2 receptor antagonists. Bioorg. Med. Chem. 7: 2635-2645.
159. Massova I, Kollman PA. 1999. Computational alanine scanning to probe protein-protein interactions: A novel approach to evaluate binding free energies. J. Am. Chem. Soc. 121: 8133-8143.
160. Mateu MG, Fersht AR. 1998. Nine hydrophobic side chains are key determinants of the thermodynamic stability and oligomerization status of tumour suppressor p53 tetramerization domain. EMBO J. 17: 2748-2758.
161. Mathews FS, Mauk AG, Moore GR. 2000. Protein-protein complexes formed by electron transfer proteins. In Protein-Protein Recognition. Oxford University Press: New York; 60-101.
162. McCammon JA. 1998. Theory of biomolecular recognition. Curr. Opin. Struct. Biol. 8: 245-249.
163. McCoy AJ, Chandana EV, Colman PM. 1997. Electrostatic complementarity at protein/protein interfaces. J. Mol. Biol. 268: 570-584.
164. McDonnell JM. 2001. Surface plasmon resonance: towards an understanding of the mechanisms of biological molecular recognition. Curr. Opin. Chem. Biol. 5: 572-577.
165. McInnes C, Grothe S, O'Connor-McCourt M, Sykes BD. 2000. NMR study of the differential contributions of residues of transforming growth factor alpha to association with its receptor. Protein Engng 13: 143-147.
166. Metcalf CA, Eyermann CJ, Bohacek RS, Haraldson CA, Varkhedkar VM, Lynch BA, Bartlett C, Violette SM, Sawyer TK. 2000. Structure-based design and solid-phase parallel synthesis of phosphorylated nonpeptides to explore hydrophobic binding at the Src SH2 domain. J. Comb. Chem. 2: 305-313.
167. Michnick SW. 2000. Chemical biology beyond binary codes. Chem. Biol. 7: R217-R221.
168. Morris MC, Robert-Hebmann V, Chaloin L, Mery J, Heitz F, Devaux C, Goody RS, Divita G. 1999. A new potent HIV-1 reverse transcriptase inhibitor. A synthetic peptide derived from the interface subunit domains. J. Biol. Chem. 274: 24941-24946.
169. Muegge I, Schweins T, Warshel A. 1998. Electrostatic contributions to protein-protein binding affinities: application to Rap/Raf interaction. Proteins 30: 407-423.
170. Murray-Rust J, McLeod AN, Blundell TL, Wood SP. 1992. Structure and evolution of insulins: implications for receptor binding. Bioessays 14: 325-331.
171. Nefzy A, Dooley C, Ostresh JM, Houghten RA. 1998. Combinatorial chemistry: from peptides and peptidomimetics to small organic and heterocyclidc compounds. Bioorg. Med. Chem. Lett. 8: 2273-2278.
172. Nguyen JT, Porter M, Amoui M, Miller WT, Zuckermann RN, Lim WA. 2000. Improving SH3 domain ligand selectivity using a non-natural scaffold. Chem. Biol. 7: 463-473.
173. Nicole P, Lins L, Rouyer-Fessard C, Drouot C, Fulcrand P, Thomas A, Couvineau A, Martinez J, Brasseur R, Laburthe M. 2000. Identification of key residues for interaction of vasoactive intestinal peptide with human VPAC(1) and VPAC(2) receptors and development of a highly selective VPAC(1) receptor agonist. Alanine scanning and molecular modeling of the peptide. J. Biol. Chem. 275: 24003-24012.
174. Niimi T, Orita M, Okazawaigarashi M, Sakashita H, Kikuchi K, Ball E, Ichikawa A, Yamagiwa Y, Sakamoto S, Tanaka A, Tsukamoto S, Fujita S, Tatsuta K, Maeda Y, Chikauchi K. 2001. Design and synthesis of non-peptidic inhibitors for the Syk C-terminal SH2 domain based on structure-based insilico screening. J. Med. Chem. 44: 4737-4740.
175. Nordhoff A, Tziatzios C, van den Broek JA, Schott MK, Kalbitzer HR, Becker K, Schubert D, Schirmer RH. 1997. Denaturation and reactivation of dimeric human glutation reductase - an assay for folding inhibitors. Eur. J. Biochem. 245: 273-282.
176. Norton JD, Deed RW, Craggs G, Sablitzky F. 1998. Id helix-loop-helix proteins in cell growth and differentiation. Trends Cell Biol. 8: 58-65.
177. Okada D. 1998. Tetrahydrobiopterin-dependent stabilization of neuronal nitric oxide synthase dimer reduces susceptibility to phosphorylation by protein kinase C in vitro. FEBS Lett. 434: 261-264.
178. Omata Y, Dai RK, Smith SV, Robinson RC, Friedman FK. 2000. Synthetic peptide mimics of a predicted topographical interaction surface: the cytochrome P4502B1 recognition domain for NADPH-cytochrome P450 reductase. J. Protein Chem. 19: 23-32.
179. Onofri F, Giovedi S, Kao HT, Valtorta F, Borbone LB, De Camilli P, Greengard P, Benfenati F. 2000. Specificity of the binding of synapsin I to Src homology 3 domains. J. Biol. Chem. 275: 29857-29867.
180. Ortiz MA, Light J, Maki RA, Assa-Munt N. 1999. Mutation analysis of the Pip interaction domain reveals critical residues for protein-protein interactions. Proc. Natl Acad. Sci. USA 96: 2740-2745.
181. Otzen DE, Fersht AR. 1999. Analysis of protein-protein interactions by mutagenesis: direct versus indirect effects. Protein Engng 12: 41-45.
182. Overton MC, Blumer KJ. 2000. G-protein-coupled receptors function as oligomers in vivo. Curr. Biol. 10: 341-344.
183. Pace AJ, Gama L, Breitwieser GE. 1999. Dimerization of the calcium-sensing receptor occurs within the extracellular domain and is eliminated by Cys → Ser mutations at Cys(101) and Cys(236). J. Biol. Chem. 274: 11629-11634.
184. Pacofsky GJ, Lackey K, Alligood KJ, Berman J, Charifson PS, Crosby RM, Dorsey GF Jr, Feldman PL, Gilmer TM, Hummel CW, Jordan SR, Mohr C, Shewchuk LM, Sternbach DD, Rodriguez M. 1998. Potent dipeptide inhibitors of the pp60c-src SH2 domain. J. Med. Chem. 41: 1894-1908.
185. Pardanani A, Gambacurta A, Ascoli F, Royer WE. 1998. Mutational destabilization of the critical interface water cluster in Scapharca dimeric hemoglobin. Structural basis for altered allosteric activity. J. Mol. Biol. 284: 729-739.
186. Park SH, Raines RT. 1997. Green fluorescent protein as a signal for protein-protein interactions. Protein Sci. 6: 2344-2349.
187. Park SH, Raines RT. 2000. Genetic selection for dissociative inhibitors of designated protein-protein interactions. Nat. Biotechnol. 18: 847-851.
188. Parker SL, Parker MS. 2000. FMRF amides exert a unique modulation of rodent pancreatic polypeptide sensitive neuropeptide Y (NPY) receptors. Can. J. Physiol. Pharmac. 78: 150-161.
189. Pawson T. 1995. Protein modules and signalling networks. Nature 373: 573-580.
190. Pawson T, Gish GD, Nah P. 2001. SH2 domains, interaction modules and cellular wiring. Trends Cell Biol. 11: 504-511.
191. Pepys MB, Herbert J, Hutchinson WL, Tennent GA, Lachmann HJ, Gallimore JR, Lovat LB, Bartfai T, Alanine A, Hertel C, Hoffmann T, Jakob-Roetne R, Norcross RD, Kemp JA, Yamamura K, Suzuki M, Taylor GW, Murray S, Thompson D, Purvis A, Kolstoe S, Wood SP, Hawkins PN. 2002. Targeted pharmacological depletion of serum amyloid P component for treatment of human amyloidosis. Nature 417: 254-259.
192. Pons J, Rajpal A, Kirsch JF. 1999. Energetic analysis of an antigen/antibody interface: Alanine scanning mutagenesis and double mutant cycles on the HyHEL-10/lysozyme interaction. Protein Sci. 8: 958-968.
193. Prasanna V, Bhattacharjya S, Balaram P. 1998. Synthetic interface peptides as inactivators of multimeric enzymes: inhibitory and conformational properties of three fragments from Lactobacillus casei thymidylate synthase. Biochemistry 37: 6883-6893.
194. Prevelige PE Jr. 1998. Inhibiting virus-capsid assembly by altering the polymerisation pathway. Trends Biotechnol. 16: 61-65.
195. Rafferty SP, Boyington JC, Kulansky R, Sun PD, Malech HL. 1999. Stoichiometric arginine binding in the oxygenase domain of inducible nitric oxide synthase requires a single molecule of tetrahydrobiopterin per dimer. Biochem. Biophys. Res. Commun. 257: 344-347.
196. Ramadevi N, Rodrigues J, Roy P. 1998. A leucine zipper-like domain is essential for dimerization and encapsidation of bluetongue virus nucleocapsid protein VP4. J. Virol. 72: 2983-2990.
197. Ratovitski EA, Alam MR, Quick RK, McMillan A, Bao C, Kozlovsky C, Hand TA, Johnson RC, Mains RE, Eipper BA, Lowenstein CJ. 1999. Kalirin inhibition of inducible nitric-oxide synthase. J. Biol. Chem. 274: 993-999.
198. Rich RL, Myszka DG. 2001. Survey of the year 2000 commercial optical biosensor literature. J. Mol. Recognit. 14: 273-294.
199. Rickles RJ, Henry PA, Guan W, Azimioara M, Shakespeare WC, Violette S, Zoller MJ. 1998. A novel mechanism-based mammalian cell assay for the identification of SH2-domain-specific protein-protein inhibitors. Chem. Biol. 5: 529-538.
200. Ripka AS, Rich DH. 1998. Peptidomimetic design. Curr. Opin. Chem. Biol. 2: 441-452.
201. Rodriguezcrespo I, Straub W, Gavilanes F, Demontellano PRO. 1998. Binding of dynein light chain (PIN) to neuronal nitric oxide synthase in the absence of inhibition. Arch. Biochem. Biophys. 359: 297-304.
202. Rohrer SP, Birzin ET, Mosley RT, Berk SC, Hutchins SM, Shen D-M, Xiong Y, Hayes EC, Parmar RM, Foor F, Mitra SW, Degrado SJ, Shu M, Klopp JM, Cai SJ, Blake A, Chan WW, Pasternak A, Yang L, Patchett AA, Smith RG, Chapman KT, Schaeffer JM. 1998. Rapid identification of subtype-selective agonists of the somastatin receptor through combinatorial chemistry. Science 282: 737-740.
203. Rudert F, Woltering C, Frisch C, Rottenberger C, Ilag LL. 1998. A phage-based system to select multiple protein-protein interactions simultaneously from combinatorial libraries. FEBS Lett. 440: 135-140.
204. Rudiger AH, Rudiger M, Carl UD, Chakraborty T, Roepstorff P, Wehland J. 1999. Affinity mass spectrometry-based approaches for the analysis of protein-protein interaction and complex mixtures of peptide-ligands. Anal. Biochem. 275: 162-170.
205. Saarela J, Laine M, Tikkanen R, Oinonen C, Jalanko A, Rouvinen J, Peltonen L. 1998. Activation and oligomerization of aspartylglucosaminidase. J. Biol. Chem. 273: 25320-25328.
206. Saito S, Watabe S, Ozaki H, Kobayshi M, Suzuki T, Kobayshi H, Fusetani N, Karaki H. 1998. Actin-depolymerizing effect of dimeric macrolides, bistheonellide A and swinholide A. J. Biochem. 123: 571-578.
207. Salahpour A, Angers S, Bouvier M. 2000. Functional significance of oligomerization of G-protein-coupled receptors. Trends Endocrinol. Metab. 11: 163-168.
208. Salzmann M, Bachmann MF. 1998. The role of T cell receptor dimerization for T cell antagonism and T cell specificity. Mol. Immunol. 35: 271-277.
209. Sasvari Z, Asboth B. 1998. Formation of disulfide-bridges dimers during theroinactivation of glucoamylase from Aspergillus niger. Enzyme Microb. Technol. 22: 466-470.
210. Schenkman JB, Jansson I. 1999. Interactions between cytochrome P450 and cytochrome b5. Drug Metab. Rev. 31: 351-364.
211. Schoepfer J, Gay B, Caravatti G, Garcia-Echeverria C, Fretz H, Rahuel J, Furet P. 1998. Structure-based design of peptidomimetic ligands of the Grb2-SH2 domain. Bioorg. Med. Chem. Lett. 8: 2865-2870.
212. Schoepfer J, Fretz H, Gay B, Furet P, Garcia-Echeverria C, End N, Caravatti G. 1999. Highly potent inhibitors of the Grb2-SH2 domain. Bioorg. Med. Chem. Lett. 9: 221-226.
213. Schramm HJ, Derosny E, Reboudravaux M, Buttner J, Dick A, Schramm W. 1999. Lipopeptides as dimerization inhibitors of HIV-1 protease. Biol. Chem. 380: 593-596.
214. Schreiber G, Frisch C, Fersht AR. 1997. The role of Glu73 of barnase in catalysis and the binding of barstar. J. Mol. Biol. 270: 111-122.
215. Schuck P, Millar DB, Kortt AA. 1998. Determination of binding constants by equilibrium titration with circulating sample in a surface plasmon resonance biosensor. Anal. Biochem. 265: 79-91.
216. Schumacher C, Wang H, Honer C, Ding W, Koehn J, Lawrence Q, Coulis CM, Wang LL, Ballinger D, Bowen BR, Wagner S. 2000. The SCAN domain mediates selective oligomerization. J. Biol. Chem. 275: 17173-17179.
217. Scott S, Dong FM, Kisterswoike B, Mullerhill B. 2000. Dimerisation mutants of Lac repressor. II. A singe amino acid substitution, D278L, changes the specificity of dimerisation. J. Mol. Biol. 296: 673-684.
218. Selkoe DJ. 1998. The cell biology of b-amyloid precursor protein and presenilin in Alzheimer's disease. Trends Cell Biol. 8: 443-457.
219. Sengchanthalangsy LL, Datta S, Huang DB, Anderson E, Braswell EH, Ghosh G. 1999. Characterization of the dimer interface of transcription factor NF kappa B p50 homodimer. J. Mol. Biol. 289: 1029-1040.
220. Sennequier N, Wolan D, Stuehr DJ. 1999. Antifungal imidazoles block assembly of inducible NO synthase into an active dimer. J. Biol. Chem. 274: 930-938.
221. Shakespeare WC. 2001. SH2 domain inhibition: a problem solved? Curr. Opin. Chem. Biol. 5: 409-415.
222. Shakespeare W, Yang M, Bohacek R, Cerasoli F, Stebbins K, Sundaramoorthi R, Azimioara M, Vu C, Pradeepan S, Metcalf C III, Haraldson C, Merry T, Dalgarno D, Narula S, Hatada M, Lu X, van Schravendijk MR, Adams S, Violette S, Smith J, Guan W, Bartlett C, Herson J, Iuliucci J, Weigele M, Sawyer T. 2000. Structure-based design of an osteoclast-selective, nonpeptide Src homology 2 inhibitor with in vivo antiresorptive activity. Proc. Natl Acad. Sci. USA 97: 9373-9378.
223. Sheinerman FB, Norel R, Honig B. 2000. Electrostatic aspects of protein-protein interactions. Curr. Opin. Struct. Biol. 10: 153-159.
224. Shima S, Tziatzios C, Schubert D, Fukada H, Takahashi K, Ermler U, Thauer RK. 1998. Lyotropic-salt induced changes in monomer/dimer/tetramer association equilibrium of formyl-transferase from the hyperthermophilic Methanopyrus kandleri in relation to the activity and thermostability of the enzyme. Eur. J. Biochem. 258: 85-92.
225. Shultz MD, Chmielewski J. 1997. Hydrophobicity versus activity in crosslinked interfacial peptide inhibitor of HIV-1 protease. Tetrahedron 8: 3881-3886.
226. Shultz MD, Chmielewski J. 1999. Probing the role of interfacial residues in a dimerization inhibitor of HIV-1 protease. Bioorg. Med. Chem. Lett. 9: 2431-2436.
227. Shultz MD, Bowman MJ, Ham YW, Zhao XM, Tora G, Chmielewski J. 2000. Small-molecule inhibitors of HIV-1 protease dimerization derived from cross-linked interfacial peptides. Angew. Chem. 39: 2710-2713.
228. Singh SK, Maithal K, Balaram H, Balaram P. 2001. Synthetic peptides as inactivators of multimeric enzymes: inhibition of Plasmodium falciparum triosephosphate isomerase by interface peptides. FEBS Lett. 501: 19-23.
229. Sloan DJ, Hellinga HW. 1998. Structure-based engineering of environmentally sensitive fluorophores for monitoring protein-protein interactions. Protein Engng 11: 819-823.
230. Smith KM, Vanetten RA. 2001. Activation of c-Abl kinase activity and transformation by a chemical inducer of dimerization. J. Biol. Chem. 276: 24372-24379.
231. Smyczynski C, Derancourt J, Chaussepied P. 2000. Regulation of ncd by oligomeric state of tubulin. J. Mol. Biol. 295: 325-336.
232. Song MC, Rajesh S, Hayashi Y, Kiso Y. 2001. Design and synthesis of new inhibitors of HIV-1 protease dimerization with conformationally constrained templates. Bioorg. Med. Chem. Lett. 11: 2465-2468.
233. Songyang Z, Fanning AS, Fu C, Xu J, Marfatia SM, Chishti AH, Crompton A, Chan AC, Anderson JM, Cantley LC. 1997. Recognition of unique carboxyl-terminal motifs by distinct PDZ domains. Science 275: 73-77.
234. Sourgen F, Maroun RG, Frere V, Bouziane M, Auclair C, Troalen F, Fermandjian S. 1996. A synthetic peptide from the human immunodeficiency virus type-1 integrase exibits coiled-ciol properties and interfaces with the in vitro integration activity of the enzyme. Eur. J. Biochem. 240: 765-773.
235. Souroujon MC, Mochly-Rosen D. 1998. Peptide modulators of protein-protein interactions in intracellular signaling. Nat. Biotechnol. 16: 919-924.
236. Srivastava AK, Sauer RT. 2000. Evidence for partial secondary structure formation in the transition state for Arc repressor refolding and dimerization. Biochemistry 39: 8308-8314.
237. Stenberg G, Abdalla AM, Mannervik B. 2000. Tyrosine 50 at the subunit interface of dimeric human glutathione transferase P1-1 is a structural key residue for modulating protein stability and catalytic function. Biochem. Biophys. Res. Commun. 271: 59-63.
238. Stevens JM, Armstrong RN, Dirr HW. 2000. Electrostatic interactions affecting the active site of class Sigma glutathione S-transferase. Biochem. J. 347: 193-197.
239. Stigers KD, Soth MJ, Nowick JS. 1999. Designed molecules that fold to mimic protein secondary structures. Curr. Opin. Chem. Biol. 3: 714-723.
240. Stites WE. 1997. Protein-protein interactions: interface structure, binding thermodynamics, and mutational analysis. Chem. Rev. 97: 1233-1250.
241. Sundberg EJ, Mariuzza RA. 2000. Luxury accommodations: the expanding role of structural plasticity in protein-protein interactions. Struct. Fold. Des. 8: R137-R142.
242. Sundberg EJ, Urrutia M, Braden BC, Isern J, Tsuchiya D, Fields BA, Malchiodi EL, Tormo J, Schwarz FP, Mariuzza RA. 2000. Estimation of the hydrophobic effect in an antigen-antibody protein-protein interface. Biochemistry 39: 15375-15387.
243. Tamura A, Privalov PL. 1997. The entropy cost of protein association. J. Mol. Biol. 273: 1048-1060.
244. Taniguchi H. 1999. Protein myristoylation in protein-lipid and protein-protein interactions. Biophys. Chem. 82: 129-137.
245. Tarasova NI, Rice WG, Michejda CJ. 1999. Inhibition of G-protein-coupled receptor function by disruption of transmembrane domain interactions. J. Biol. Chem. 274: 34911-34915.
246. Thomas MC, Ballantine SP, Bethell SS, Bains S, Kellam P, Delves CJ. 1998. Single amino acid substitutions disrupt tetramer formation in the dihydroneopterin aldolase enzyme of Pneumocystis carinii. Biochemistry 37: 11629-11636.
247. Tochio H, Zhang Q, Mandal P, Li M, Zhang M. 1999. Solution structure of neuronal nitric oxide synthase PDZ domain complexed with an associated peptide. Nat. Struct. Biol. 6: 417-421.
248. Tsai C-J, Lin SL, Wolfson HJ, Nissinov R. 1996. Protein-protein interfaces: Architectures and interactions in protein-protein interfaces and in protein cores. Their similarities and differences. Crit. Rev. Biochem. Mol. Biol. 31: 127-152.
249. Tsai C-J, Lin SL, Wolfson HJ, Nissinov R. 1997a. Studies of protein-protein interfaces: a statistical analysis of hydrophobic effect. Protein Sci. 6: 53-64.
250. Tsai C-J, Xu D, Nissinov R. 1997b. Structural motifs at protein-protein interfaces: protein cores versus two-state and three-state model complexes. Protein Sci. 6: 1797-1809.
251. Tsuda T, Ikeda Y, Taniguchi N, 2000. The Asn-420-linked sugar chain in human epidermal growth factor receptor suppresses ligand-independent spontaneous oligomerization - possible role of a specific chain in controllable receptor activation. J. Biol. Chem. 275: 21988-21994.
252. Ubarretxena-Belandia I, Hozeman L, Vanderbrinkvanderlaan E, Pap EHM, Egmond MR, Verheij HM, Dekker N. 1999. Outer membrane phospholipase A is dimeric in phospholipid bilayers: a cross-linking and fluorescence resonance energy transfer study. Biochemistry 38: 7398-7405.
253. Ulysse LG, Chmielewski J. 1998. Restricting the flexibility of crosslinked, interfacial peptide inhibitors of HIV-1 protease. Bioorg. Med. Chem. Lett, 8: 3281-3286.
254. Usui T, Kondoh M, Mayumi T, Osada H. 1998. Tryptostatin A, a specific and novel inhibitor of microtubule assembly. Biochem. J. 333: 543-548.
255. Valentemesquita VL, Botelho MM, Ferreira ST. 1998. Pressure-induced subunit dissociation and unfolding of dimeric betalactoglobulin. Biophys. J. 75: 471-476.
256. Vaughan CK, Buckle AM, Fersht AR. 1999. Structural response to mutation at a protein-protein interface. J. Mol. Biol. 286: 1487-1506.
257. Velev OD, Kaler EW, Lenhoff AM. 1998. Protein interactions in solution characterized by light and neutron scattering: comparison of lysozyme and chymotrypsinogen. Biophys. J. 75: 2682-2697.
258. Vergnon AL, Chu YH. 1999. Electrophoretic methods for studying protein-protein interactions. Methods 19: 270-277.
259. Viani MB, Pietrasanta LI, Thompson JB, Chand A, Gebeshuber IC, Kindt JH, Richter M, Hansma HG, Hansma PK. 2000. Probing protein-protein interactions in real time. Nat. Struct. Biol. 7: 644-647.
260. Vijayakumar M, Wong KY, Schreiber G, Fersht AR, Szabo A, Zhou HX. 1998. Electrostatic enhancement of diffusion-controlled protein-protein association: comparison of theory and experiment on barnase and barstar. J. Mol. Biol. 278: 1015-1024.
261. Violette SM, Shakespeare WC, Bartlett C, Guan W, Smith JA, Rickles RJ, Bohacek RS, Holt DA, Baron R, Sawyer TK. 2000. A Src SH2 selective binding compound inhibits osteoclastmediated resorption. Chem. Biol. 7: 225-235.
262. von Kries JP, Winbeck G, Asbrand C, Schwarz-Romond T, Sochnikova N, Dell'oro A, Behrens J, Birchmeier W. 2000. Hot spots in beta-catenin for interactions with LEF-1, conductin and APC. Nat. Struct. Biol. 7: 800-807.
263. Vu CB. 2000. Recent advances in the design and synthesis of SH2 inhibitors of Src Grb2 and ZAP-70. Curr. Med. Chem. 7: 1081-1100.
264. Vu CB, Corpuz EG, Merry TJ, Pradeepan SG, Bartlett C, Bohacek RS, Botfield MC, Eyermann CJ, Lynch BA, MacNeil IA, Ram MK, van Schravendijk MR, Violette S, Sawyer TK. 1999. Discovery of potent and selective SH2 inhibitors of the tyrosine kinase ZAP-70. J. Med. Chem. 42: 4088-4098.
265. Walker CV, Caravatti G, Denholm AA, Egerton J, Faessler A, Furet P et al. 2000. Structure-based design and synthesis of phosphinate isosteres of phosphotyrosine for incorporation in Grb2-SH2 domain inhibitors. Part 2. Bioorg. Med. Chem. Lett. 10: 2343-2346.
266. Wall MA, Posner BA, Sprang SR. 1998. Structural basis of activity and subunit recognition in G protein heterotrimers. Structure 6: 1169-1183.
267. Wallace LA, Dirr HW. 1999. Folding and assembly of dimeric human glutathione transferase A1-1. Biochemistry 38: 16686-16694.
268. Way JC. 2000. Covalent modification as a strategy to block protein-protein interactions with small-molecule drugs. Curr. Opin. Chem. Biol. 4: 40-46.
269. Wells JA. 1996. Binding in the growth hormone receptor complex. Proc. Natl Acad. Sci. USA 93: 1-6.
270. Witter DJ, Famiglietti SJ, Cambier JC, Castelhano AL. 1998. Design and synthesis of SH3 domain binding ligands: modifications of the consensus sequence XPpXP. Bioorg. Med. Chem. Lett. 8: 3137-3142.
271. Wlodawer A, Vondrasek J. 1998. Inhibitors of HIV-1 protease: a major success of structure-assisted drug design. A. Rev. Biophys. Biomol. Struct. 27: 249-284.
272. Xie ZH, Schendel S, Matsuyama S, Reed JC. 1998. Acidic pH promotes dimerization of Bcl-2 family proteins. Biochemistry 37: 6410-6418.
273. Xie D, Gulnik S, Gustchina E, Yu B, Shao W, Qoronfleh W, Nathan A, Erickson JW. 1999. Drug resistance mutations can affect dimer stability of HIV-1 protease at neutral pH. Protein Sci. 8: 1702-1707.
274. Xu D, Lin SL, Nussinov R. 1997a. Protein binding versus protein folding: the role of hydrophilic bridges in protein associations. J. Mol. Biol. 265: 68-84.
275. Xu D, Tsai C-J, Nussinov R. 1997b. Hydrogen bonds and salt bridges across protein-protein interfaces. Protein Engng 10: 999-1012.
276. Yang W, Rozamus LW, Narula S, Rollins CT, Yuan R, Andrade LJ, Ram MK, Phillips TB, van Schravendijk MR, Dalgarno D, Clackson T, Holt DA. 2000. Investigating protein-ligand interactions with a mutant FKBP possessing a designed specificity pocket. J. Med. Chem. 43: 1135-1142.
277. Yanofsky SD, Baldwin DN, Butler JH, Holden FR, Jacobs JW, Balasubramanian P, Chinn JP, Cwirla SE, Peters-Bhatt E, Whitehorn EA., Tate EH, Akeson A, Bowlin TL, Dower WJ, Barrett RW. 1996. High affinity type 1 interleukin-1 receptor antagonists discovered by screening recombinant peptide libraries. Proc. Natl Acad. Sci. USA 93: 7381-7386.
278. Yao S, Brickner M, Paresmatos EI, Chmielewski J. 1998. Uncoiling c-Jun coiled coils: Inhibitory effects of truncated fos peptides on jun dimerization and DNA binding in vitro. Biopolymers 47: 277-283.
279. Yao ZJ, King CR, Cao T, Kelley J, Milne GWA, Voigt JH, Burke TR. 1999. Potent inhibition of Grb2 SH2 domain binding by non-phosphate-containing ligands. J. Med. Chem. 42: 25-35.
280. Yeung D, Gill A, Maule CH, Davies RJ. 1995. Detection and quantification of biomolecular interactions with optical biosensors. Trends Anal. Chem. 14: 49-56.
281. Yonehara M, Minami Y, Kawata Y, Nagai J, Yahara I. 1996. Heat-induced chaperone activity of HSP90. J. Biol. Chem. 271: 2641-2645.
282. Yudt MR, Koide S. 2001. Preventing estrogen receptor action with dimer-interface peptides. Steroids 66: 549-558.
283. Zeden-Lutz G, Zuber E, Witz J, Van Regenmortel MH. 1997. Thermodynamic analysis of antigen-antibody binding using biosensor measurements at different temperatures. Anal. Biochem. 246: 123-132.
284. Zeng J. 2000. Mini-review: computational structure-based design of inhibitors that target protein surfaces. Combin. Chem. High-Throughput Screen. 3: 355-362.
285. Zeng J, Fridman M, Maruta H, Treutlein HR, Simonson T. 1999. Protein-protein recognition: an experimental and computational study of the R89K mutation in Raf and its effect on Ras binding. Protein Sci. 8: 50-64.
286. Zhang X, Morera S, Bates PA, Whitehead PC, Coffer AI, Hainbucher K, Nash RA, Sternberg MJ, Lindahl T, Freemont PS. 1998. Structure of an XRCC1 BRCT do main: a new protein-protein interaction module. EMBO J. 17: 6404-6411.
287. Zutshi R, Chmielewski J. 2000. Targeting the dimerization interface for irreversible inhibition of HIV-1 protease. Bioorg. Med. Chem. Lett. 10: 1901-1903.
288. Zutshi R, Franciskovich J, Shultz M, Schweitzer B, Bishop P, Wilson M, Chmielewski J. 1997. Targeting the dimerization interface of HIV-1 protease: inhibition with cross-linked interfacial peptides. J. Am. Chem. Soc. 119: 4841-4845.
289. Zutshi R, Brickner M, Chmielewski J. 1998. Inhibiting the assembly of protein-protein interfaces. Curr. Opin. Chem. Biol. 2: 62-65.